Chronological improvement of survival in patients with advanced gastric cancer over 15 years.

"TO reports personal fees from ONO Pharmaceutical, personal fees from BMS, personal fees from Taiho, personal fees from Daichi-Sankyo, outside the submitted work; YN reports grants and personal fees from ONO Pharmaceutical, grants and personal fees from Bristol-Mayers Squibb, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi Sankyo, grants and personal fees from Yakult Honsha, personal fees from Taiho, personal fees from Eli Lilly, outside the submitted work; YM reports personal fees from MSD, personal fees from Lilly Japan, personal fees from Takeda, personal fees from Bristol Myers Squibb, personal fees from Taiho, outside the submitted work; KH reports grants from Pfizer, outside the submitted work; TM reports grants and personal fees from MSD, grants and personal fees from Amgen, grants and personal fees from ONO Pharmaceutical, grants and personal fees from Daiichi Sankyo, grants from Novartis, grants from Pfizer, personal fees from Taiho, personal fees from Bristol Myers Squibb, personal fees from Eli Lilly, personal fees from Takeda, grants from Boehringer-Ingelheim, grants from Syneos Health Clinical, personal fees from Chugai, personal fees from Nippon Kayaku, grants from Cimic Shift Zero, personal fees from Merck Bio Pharma, personal fees from Bayer, personal fees from Yakult Honsha, personal fees from Sanofi, personal fees from ONO Pharmaceutical, outside the submitted work; HT reports grants and personal fees from Takeda, grants from Daiichi Sankyo, grants and personal fees from ONO Pharmaceutical, personal fees from Eli Lilly, personal fees from Merck Biopharma, personal fees from Chugai, outside the submitted work; SK reports grants and personal fees from Eli Lilly, grants from Nobelpharma, grants and personal fees from Taiho, grants and personal fees from MSD, grants and personal fees from Bayer, grants from Yansen, grants and personal fees from Chugai, grants and personal fees from ONO Pharmaceutical, grants from Daiichi Sankyo, personal fees from Merck, personal fees from BMS, outside the submitted work; MA reports personal fees from Eisai Co., Ltd, personal fees from ONO Pharmaceutical, personal fees from Chugai Pharmaceutical Co. Ltd, personal fees from Mundipharma Co., Ltd, personal fees from Taiho Pharmaceutical Co., Ltd, outside the submitted work; SI reports grants from ONO Pharmaceutical, grants from Merck Sharp & Dohme, grants from AstraZeneca, personal fees from Taiho Pharmaceutical, personal fees from Otsuka, outside the submitted work; MT reports personal fees from Bristol Myers Squibb, outside the submitted work; KM reports grants from Chugai, grants and personal fees from MSD, grants and personal fees from Amgen, grants and personal fees from ONO Pharmaceutical, grants from Astellas, grants from Sanofi, grants from Taiho, grants from Eisai, grants and personal fees from Daiichi Sankyo, grants from Novartis, grants from Pfizer, personal fees from AstraZeneca, personal fees from Taiho, personal fees from Bristol Myers Squibb, personal fees from Eli Lilly, personal fees from Takeda, outside the submitted work; others have declared no potential conflicts of interest."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."